Business Wire

ESI Group at the Farnborough International Airshow 2022

18.7.2022 09:00:00 EEST | Business Wire | Press release

Share

Regulatory News:

ESI Group (ISIN Code: FR0004110310, Symbol: ESI) (Paris:ESI) , a global simulation and virtual prototyping software partner for the industry, will be present at the Farnborough International Airshow (18 and 22 July 2022). ESI Group will present an outline of aircraft Acoustics for both interior and exterior noise. Besides, The Group will illustrate how virtual reality solutions help power industry 4.0, showcasing and demonstrating its solution for human-centric virtual simulation and collaborative work with IC.IDO.

2 software solutions presented:

  • ESI’s flagship Virtual Reality software IC.IDO for human-centric process validation and product integration: facilitating agile design processes, robust manufacturing, and safe maintenance operations.
  • ESI’s vibro-acoustics software VA ONE for aircraft interiors and electric aircraft like eVTOL concepts: meeting interior noise level comfort and optimizing exterior noise impact in urban areas

Promising progress in the aircraft industry thanks to digitalization and virtual reality

Digitalization plays a major role in developing sustainable aviation, hydrogen planes, electric aircraft, urban mobility, eVTOLs... Virtual reality helps industries achieve sustainability goals, to secure “first time right”, reduce costs, time and go to market. Throughout the years, Virtual reality upgraded processes, allowing faster turnaround for foundries and composite parts manufacturers, lower scrap rates, manufacturability despite new geometries. Industrials have been able to achieve their desired vibro-acoustic performance and virtually pre-certified products. Besides, the need for physical try-outs and prototypes significantly decreased, paving the way to more efficient assembly steps, increased productivity and output, reduced maintenance costs, and decreased industrial risks for operators.

ESI Group has been operating in the aircraft industry for the last decades. ESI’s aerospace customers leverage the benefits of virtual reality solutions, helping them achieve their goal to producing clean, safe, and productive.

eVTOLS: ESI Group helps foster innovations – interior external noise and comfort

ESI has the mission to help aerospace companies in gearing their digital transformation, to be a partner they can trust to help foster innovations, such as the eVTOLS, that will change the landscape of urban mobility. ESI Group is already helping the pioneers of that segment achieve their product performance and safety targets while meeting stringent noise regulations, reducing noise impact in urban areas and meeting interior aircraft noise comfort levels. ESI Group’s VA One software solution help manufacturers to predict and resolve potential noise and vibration challenges in very early stages of their development process. Thus, meeting safety standards and their objectives for aircraft acoustics, and minimizing weight and controlling costs.

ESI Group’s software solutions for a clean, safe, and productive industry

1. Power systems manufacturer Rolls-Royce uses ESI casting simulation software ProCAST for Product-Process co-design and to collaborate more efficiently with their supply chain towards greater quality parts, avoiding late design changes and eliminating scrap rates in a more sustainable manner.

2. Saab Aerospace Systems relies on ESI composites manufacturing simulation software PAM-COMPOSITES to refine their injection strategies for the next generation aircraft doors, supporting the advanced manufacturing of ever lighter structures.

3. Latécoère counts on the advanced virtual reality capabilities provided by IC.IDO (1), to connect manufacturing engineering teams from around the world on the same virtual platform to secure “First Time Right” production and to train operators remotely, cutting down on travel emissions, yet providing a “learning by doing” approach.

(1) ESI Group at the exhibition: France Pavillion. ESI Group will be part of the GIFAS (& “AsTech”) area in HALL 1 – Booth 13.60 Village ASTech

About ESI Group

Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high-stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world, and reported 2021 sales of €136.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com.

Follow ESI: LinkedIn | Facebook | Twitter | YouTube

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ESI Group
Florence Barré
press@esi-group.com
+33 1 49 78 28 28

Verbatee - Press & Shareholder Relations
Jérôme Goaer, j.goaer@verbatee.com, +33 6 61 61 79 34
Aline Besselièvre, a.besselievre@verbatee.com, +33 6 61 85 10 05

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release

Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release

Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 11:00:00 EEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 11:00:00 EEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye